For patients with symptomatic condition necessitating therapy, ibrutinib is commonly recommended depending on 4 section III randomized scientific trials comparing ibrutinib with chlorambucil monotherapy106 along with other normally used CIT combinations, namely FCR, bendamustine additionally rituximab and chlorambucil as well as obinutuzumab (ClbO)… Read More